Evidence map›Paper›PMID 38873351›Full record

ArticleBJUI compass2024

'It Just Makes Sense to Me': A qualitative study exploring patient decision-making and experiences with prostate MRI during active surveillance for prostate cancer.

Ryan Sutherland, Cary P Gross, Xiaomei Ma, Farah Jeong, Tyler M Seibert, Matthew R Cooperberg, William J Catalona, Shellie D Ellis, Stacy Loeb, Dena Schulman-Green and 1 more

Erratum issuedAbstract read
In one paragraph

Article in BJUI compass, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Erratum.BJUI compass · 2024
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors.

Ryan SutherlandYale School of Medicine New Haven Connecticut USA.ORCID https://orcid.org/0000-0002-3821-2549
Cary P GrossYale Cancer Outcomes, Public Policy, and Effectiveness Research Center New Haven Connecticut USA.
Xiaomei MaYale Cancer Outcomes, Public Policy, and Effectiveness Research Center New Haven Connecticut USA.
Farah JeongYale School of Public Health New Haven Connecticut USA.
Tyler M SeibertDepartment of Radiation Medicine and Applied Sciences University of California San Diego La Jolla California USA.
Matthew R CooperbergDepartment of Urology University of California San Francisco San Francisco California USA.
William J CatalonaDepartment of Urology Northwestern University Feinberg School of Medicine Chicago Illinois USA.
Shellie D EllisDepartment of Population Health Kansas University Medical Center Kansas City Kansas USA.
Stacy LoebDepartments of Urology and Population Health New York University Langone Health New York USA.
Dena Schulman-GreenNew York University Rory Meyers College of Nursing New York New York USA.
Michael S LeapmanYale Cancer Outcomes, Public Policy, and Effectiveness Research Center New Haven Connecticut USA.ORCID https://orcid.org/0000-0002-0727-7614

Funding

Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9M
Targeting FOXA1-downstream pathways: a novel therapeutic strategy for castration-resistant prostate cancerP50CA180995 · NCI · NORTHWESTERN UNIVERSITY AT CHICAGO · PI ABDULKADIR, SARKI A. · 2015 to 2025
$19.9M
Understanding the Adoption and Impact of New Risk Assessment Technologies in Prostate Cancer CareK08CA237872 · NCI · YALE UNIVERSITY · PI LEAPMAN, MICHAEL STUART · 2019 to 2023
$1.1M
NCATS NIH HHS UL1 TR001863NCI NIH HHS K08 CA237872NCI NIH HHS P50 CA180995
6 · The paper itself

Abstract

Introduction: Although prostate magnetic resonance imaging (MRI) is commonly used in the diagnosis, staging and active surveillance of prostate cancer, little is known about patient perspectives on MRI. Methods: We performed a qualitative study consisting of in-depth, semi-structured interviews of patients with low- and intermediate-risk prostate cancer managed with active surveillance. Interviews focused on experiences with and knowledge of prostate MRI and MRI-ultrasound fusion biopsy during active surveillance. We purposively sampled patients who received prostate MRI as part of their clinical care, conducted interviews until reaching thematic saturation and performed conventional content analysis to analyse data. Results: Twenty patients aged 51-79 years (mean = 68 years) participated in the study. At diagnosis, 17 (85%) had a Gleason grade group 1, and three (15%) had a grade group 2 tumour. Overall, participants viewed prostate MRI as a valuable tool that accurately localizes and monitors prostate cancer over time, and they considered prostate MRI central to active surveillance monitoring. We identified five thematic categories related to MRI use: (1) the experiential aspects of undergoing an MRI scan; (2) the experience of visualizing one's own prostate and prostate cancer; (3) adequacy of provider explanations of MRI results; (4) confidence in prostate MRI in decision-making; and (5) the role of prostate MRI in longitudinal follow-up, including an interest in using MRI to modify the timing of, or replace, prostate biopsy. Conclusion: Patients value prostate MRI as a tool that enhances their confidence in the initial diagnosis and monitoring of prostate cancer. This work can inform future studies to optimize patient experience, education and counselling during active surveillance for prostate cancer.

Indexed as

active surveillancepatient‐centered researchprostate cancerprostate MRIqualitative research

Identifiers

PMID38873351
PMCPMC11168777

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.